<p>根據最近向證券交易委員會提交的文件，Principal Financial Group Inc. 在第三季度將其在 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - 免費報告) 的持股減少了 34.7%。該公司在此期間出售了 52,316 股後，持有 98,489 股這家專業製藥公司的股票。截至其最近的 SEC 文件，Principal Financial Group Inc. 擁有約 0.45% 的 ANI Pharmaceuticals，價值 9,022,000 美元。</p>
<p>獲取 <strong>ANI Pharmaceuticals</strong> 的提醒：</p>
<p>其他幾家機構投資者和對沖基金最近也調整了對 ANIP 的持股。Advisors Asset Management Inc. 在第一季度購買了約 28,000 美元的新頭寸。Caitong International Asset Management Co. Ltd 在第二季度將其在 ANI Pharmaceuticals 的股份增加了 4,636.4%。Caitong International Asset Management Co. Ltd 現在擁有 521 股這家專業製藥公司的股票，價值 34,000 美元，此前在此期間又購買了 510 股。Newbridge Financial Services Group Inc. 在第二季度將其在 ANI Pharmaceuticals 的股份增加了 200.0%。Newbridge Financial Services Group Inc. 現在擁有 600 股這家專業製藥公司的股票，價值 39,000 美元，此前在上個季度又購買了 400 股。懷俄明州購買了約 50,000 美元的新頭寸。最後，CWM LLC 在第三季度將其在 ANI Pharmaceuticals 的股份增加了 159.1%。CWM LLC 現在擁有 798 股這家專業製藥公司的股票，價值 73,000 美元，此前在此期間又獲得了 490 股。對沖基金和其他機構投資者持有該公司 76.05% 的股票。</p>
<h2>ANI Pharmaceuticals 股票表現</h2>
<p>NASDAQ:ANIP 週五開盤價為 76.70 美元。該公司的 50 日移動平均價格為 81.26 美元，200 日移動平均價格為 85.77 美元。該公司的流動比率為 2.58，速動比率為 2.04，債務與股本比率為 1.20。該公司的市值為 17.2 億美元，市盈率為 47.06，貝塔值為 0.50。ANI Pharmaceuticals, Inc. 的 12 個月最低價為 54.10 美元，最高價為 99.50 美元。</p>
<h2>ANI Pharmaceuticals 內部交易</h2>
<p>在其他新聞中，副總裁 Meredith Cook 在 1 月 13 日星期二出售了 500 股公司的股票。股票以平均價格 84.33 美元出售，總價值為 42,165.00 美元。交易完成後，副總裁直接持有 74,374 股公司股票，價值 6,271,959.42 美元。這代表其持股減少了 0.67%。該交易已在向證券交易委員會提交的文件中披露，具體信息可在此鏈接查看。此外，董事 Renee P. Tannenbaum 在 12 月 5 日星期五出售了 1,800 股 ANI Pharmaceuticals 的股票。股票以平均價格 81.15 美元出售，總價值為 146,070.00 美元。交易完成後，董事持有 25,157 股公司股票，價值約 2,041,490.55 美元。該交易使其持股減少了 6.68%。有關此銷售的更多詳細信息可在官方 SEC 披露中找到。過去 90 天內，內部人士共出售了 4,322 股公司股票，價值 354,816 美元。內部人士持有公司 11.10% 的股票。</p>
<h2>分析師評級調整</h2>
<p>幾位股票分析師對 ANIP 股票發佈了報告。Weiss Ratings 在 12 月 29 日的報告中重申了對 ANI Pharmaceuticals 股票的 “持有（c+）” 評級。Guggenheim 在 1 月 16 日的研究報告中將 ANI Pharmaceuticals 的目標價從 115.00 美元上調至 124.00 美元，並給予該股票 “買入” 評級。Barclays 在 12 月 9 日的研究報告中開始覆蓋 ANI Pharmaceuticals 的股票。他們對該股票給予了 “增持” 評級，並設定了 100.00 美元的目標價。最後，Zacks Research 在 1 月 6 日的報告中將 ANI Pharmaceuticals 的評級從 “強力買入” 下調至 “持有”。六位股票研究分析師對該股票給予了買入評級，三位分析師對公司給予了持有評級。根據 MarketBeat 的數據，ANI Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標價為 103.43 美元。</p>
<p><strong>查看我們關於 ANIP 的最新研究報告</strong></p>
<h2>關於 ANI Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>ANI Pharmaceuticals, Inc. 是一家總部位於美國的專業製藥公司，專注於仿製藥和品牌處方藥的開發、生產和商業化。該公司作為一個端到端的服務提供商，提供從活性藥物成分（API）生產和配方開發到成品劑型製造和包裝的服務。</p>
<p>ANI 的產品組合涵蓋了多個治療領域的注射和口服療法，包括內分泌學、腫瘤學、疼痛管理和呼吸護理。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，而不是 ANI Pharmaceuticals</li>
<li>Nvidia CEO 發佈大膽的特斯拉預測</li>
<li>你的銀行賬户不再安全</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>新的黃金價格目標</li>
</ul>
<p><strong>想看看其他對沖基金持有的 ANIP 嗎？</strong> 訪問 HoldingsChannel.com，獲取 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 ANI Pharmaceuticals 嗎？</h2>
<p>在考慮 ANI Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 ANI Pharmaceuticals 並不在名單上。</p>
<p>雖然 ANI Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ANI制藥

<p>Principal Financial Group Inc. 在第三季度將其在 ANI Pharmaceuticals, Inc. 的持股減少了 34.7%，目前持有 98,489 股，價值 9,022,000 美元。其他機構投資者也調整了他們的持倉。ANI Pharmaceuticals 的股票開盤價為 76.70 美元，市值為 17.2 億美元。分析師的評級各不相同，普遍共識為 “適度買入”，平均目標價為 103.43 美元。內部交易包括副總裁 Meredith Cook 和董事 Renee P. Tannenbaum 的股票出售，過去 90 天內共計 4,322 股</p>

<p>Principal Financial Group Inc. cut its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 34.7% during the third quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 98,489 shares of the specialty pharmaceutical company's stock after selling 52,316 shares during the period. Principal Financial Group Inc. owned approximately 0.45% of ANI Pharmaceuticals worth $9,022,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根據最近向證券交易委員會提交的文件，Principal Financial Group Inc. 在第三季度將其在 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - 免費報告) 的持股減少了 34.7%。該公司在此期間出售了 52,316 股後，持有 98,489 股這家專業製藥公司的股票。截至其最近的 SEC 文件，Principal Financial Group Inc. 擁有約 0.45% 的 ANI Pharmaceuticals，價值 9,022,000 美元。</p>
</div><p>Get <strong>ANI Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>ANI Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of ANIP. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the first quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd raised its stake in shares of ANI Pharmaceuticals by 4,636.4% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company's stock worth $34,000 after buying an additional 510 shares during the period. Newbridge Financial Services Group Inc. lifted its position in shares of ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock valued at $39,000 after buying an additional 400 shares in the last quarter. State of Wyoming purchased a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $50,000. Finally, CWM LLC grew its stake in ANI Pharmaceuticals by 159.1% in the 3rd quarter. CWM LLC now owns 798 shares of the specialty pharmaceutical company's stock valued at $73,000 after acquiring an additional 490 shares during the period. Hedge funds and other institutional investors own 76.05% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也調整了對 ANIP 的持股。Advisors Asset Management Inc. 在第一季度購買了約 28,000 美元的新頭寸。Caitong International Asset Management Co. Ltd 在第二季度將其在 ANI Pharmaceuticals 的股份增加了 4,636.4%。Caitong International Asset Management Co. Ltd 現在擁有 521 股這家專業製藥公司的股票，價值 34,000 美元，此前在此期間又購買了 510 股。Newbridge Financial Services Group Inc. 在第二季度將其在 ANI Pharmaceuticals 的股份增加了 200.0%。Newbridge Financial Services Group Inc. 現在擁有 600 股這家專業製藥公司的股票，價值 39,000 美元，此前在上個季度又購買了 400 股。懷俄明州購買了約 50,000 美元的新頭寸。最後，CWM LLC 在第三季度將其在 ANI Pharmaceuticals 的股份增加了 159.1%。CWM LLC 現在擁有 798 股這家專業製藥公司的股票，價值 73,000 美元，此前在此期間又獲得了 490 股。對沖基金和其他機構投資者持有該公司 76.05% 的股票。</p>
</div><h2>ANI Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>ANI Pharmaceuticals 股票表現</h2>
</div><p>NASDAQ:ANIP opened at $76.70 on Friday. The company's 50-day moving average price is $81.26 and its 200-day moving average price is $85.77. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. The company has a market cap of $1.72 billion, a P/E ratio of 47.06 and a beta of 0.50. ANI Pharmaceuticals, Inc. has a twelve month low of $54.10 and a twelve month high of $99.50.</p>
<div class="lb-trans"><p>NASDAQ:ANIP 週五開盤價為 76.70 美元。該公司的 50 日移動平均價格為 81.26 美元，200 日移動平均價格為 85.77 美元。該公司的流動比率為 2.58，速動比率為 2.04，債務與股本比率為 1.20。該公司的市值為 17.2 億美元，市盈率為 47.06，貝塔值為 0.50。ANI Pharmaceuticals, Inc. 的 12 個月最低價為 54.10 美元，最高價為 99.50 美元。</p>
</div><h2>Insider Transactions at ANI Pharmaceuticals</h2>
<div class="lb-trans"><h2>ANI Pharmaceuticals 內部交易</h2>
</div><p>In other news, VP Meredith Cook sold 500 shares of the company's stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the sale, the vice president directly owned 74,374 shares in the company, valued at $6,271,959.42. This represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, Director Renee P. Tannenbaum sold 1,800 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the transaction, the director owned 25,157 shares in the company, valued at approximately $2,041,490.55. The trade was a 6.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 4,322 shares of company stock worth $354,816 in the last ninety days. Insiders own 11.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，副總裁 Meredith Cook 在 1 月 13 日星期二出售了 500 股公司的股票。股票以平均價格 84.33 美元出售，總價值為 42,165.00 美元。交易完成後，副總裁直接持有 74,374 股公司股票，價值 6,271,959.42 美元。這代表其持股減少了 0.67%。該交易已在向證券交易委員會提交的文件中披露，具體信息可在此鏈接查看。此外，董事 Renee P. Tannenbaum 在 12 月 5 日星期五出售了 1,800 股 ANI Pharmaceuticals 的股票。股票以平均價格 81.15 美元出售，總價值為 146,070.00 美元。交易完成後，董事持有 25,157 股公司股票，價值約 2,041,490.55 美元。該交易使其持股減少了 6.68%。有關此銷售的更多詳細信息可在官方 SEC 披露中找到。過去 90 天內，內部人士共出售了 4,322 股公司股票，價值 354,816 美元。內部人士持有公司 11.10% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>Several equities analysts have issued reports on ANIP shares. Weiss Ratings reaffirmed a &#34;hold (c+)&#34; rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, January 16th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an &#34;overweight&#34; rating and a $100.00 price target on the stock. Finally, Zacks Research cut ANI Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $103.43.</p>
<div class="lb-trans"><p>幾位股票分析師對 ANIP 股票發佈了報告。Weiss Ratings 在 12 月 29 日的報告中重申了對 ANI Pharmaceuticals 股票的 “持有（c+）” 評級。Guggenheim 在 1 月 16 日的研究報告中將 ANI Pharmaceuticals 的目標價從 115.00 美元上調至 124.00 美元，並給予該股票 “買入” 評級。Barclays 在 12 月 9 日的研究報告中開始覆蓋 ANI Pharmaceuticals 的股票。他們對該股票給予了 “增持” 評級，並設定了 100.00 美元的目標價。最後，Zacks Research 在 1 月 6 日的報告中將 ANI Pharmaceuticals 的評級從 “強力買入” 下調至 “持有”。六位股票研究分析師對該股票給予了買入評級，三位分析師對公司給予了持有評級。根據 MarketBeat 的數據，ANI Pharmaceuticals 目前的共識評級為 “適度買入”，平均目標價為 103.43 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on ANIP</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 ANIP 的最新研究報告</strong></p>
</div><h2>About ANI Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 ANI Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.</p>
<div class="lb-trans"><p>ANI Pharmaceuticals, Inc. 是一家總部位於美國的專業製藥公司，專注於仿製藥和品牌處方藥的開發、生產和商業化。該公司作為一個端到端的服務提供商，提供從活性藥物成分（API）生產和配方開發到成品劑型製造和包裝的服務。</p>
</div><p>ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.</p>
<div class="lb-trans"><p>ANI 的產品組合涵蓋了多個治療領域的注射和口服療法，包括內分泌學、腫瘤學、疼痛管理和呼吸護理。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than ANI Pharmaceuticals</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>New gold price target</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 ANI Pharmaceuticals</li>
<li>Nvidia CEO 發佈大膽的特斯拉預測</li>
<li>你的銀行賬户不再安全</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>新的黃金價格目標</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ANIP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 ANIP 嗎？</strong> 訪問 HoldingsChannel.com，獲取 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ANIP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 ANI Pharmaceuticals 嗎？</h2>
</div><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 ANI Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 ANI Pharmaceuticals 並不在名單上。</p>
</div><p>While ANI Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ANI Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

信安金融集團降低了在 ANI 製藥公司中的持股比例